Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)

NCT01581593 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immunodeficiency
Agammaglobulinemia
Hypogammaglobulinemia
Antibody Deficiency

Interventions

BIOLOGICAL: Kedrion IVIG 10%

Sponsor

Kedrion S.p.A.